Skip to content

Hospital variation in medical and surgical treatment of patent ductus arteriosus.

CPQCC Publication
TitleHospital variation in medical and surgical treatment of patent ductus arteriosus.
Publication TypeJournal Article
Year of Publication2015
AuthorsLee HC, Durand DJ, Danielsen B, Dueñas GVillarin, Powers RJ
JournalAm J Perinatol
Volume32
Issue4
Pagination379-86
Date Published2015 Mar
ISSN1098-8785
KeywordsBirth Weight, California, Cyclooxygenase Inhibitors, Ductus Arteriosus, Patent, Female, Gestational Age, Hospitals, Humans, Ibuprofen, Indomethacin, Infant, Newborn, Infant, Premature, Infant, Very Low Birth Weight, Ligation, Logistic Models, Male, Odds Ratio, Practice Patterns, Physicians', Respiratory Distress Syndrome, Newborn, Risk Factors
Abstract

OBJECTIVE: This study aims to characterize population risks for diagnosis, medical treatment, and surgical ligation of patent ductus arteriosus (PDA) in very low-birth-weight infants.

STUDY DESIGN: Maternal and neonatal data were collected in 40 hospitals in California during 2011 for infants with birth weight ≤ 1,500 g without any congenital malformation, with a diagnosis of PDA. Multivariable logistic regression was used to determine independent risks for PDA diagnosis and for surgical ligation.

RESULTS: There were 770/1,902 (40.4%) infants diagnosed with PDA. Low birth weight, gestational age, respiratory distress syndrome, and surfactant administration were associated with PDA diagnosis. Ligation occurred in 43% of patients with birth weight ≤ 750 g, in 24% of patients weighing between 715 and 1,000 g, and in 12% of patients weighing from 1,001 to 1,500 g. Older gestational age (1 week, odds ratio 0.55, 95% confidence interval 0.48-0.63) and absence of respiratory distress syndrome (odds ratio 0.14, 95% confidence interval 0.03-0.59) were associated with lower ligation risk. The median hospital ligation rate was 14% (interquartile range 0-38%).

CONCLUSION: Most patients with PDA receive treatment for closure. Practice variation may set the stage for further exploration of experimental trials.

DOI10.1055/s-0034-1387931
Alternate JournalAm J Perinatol
PubMed ID25241108
Grant ListK23HD068400 / HD / NICHD NIH HHS / United States